BioSpace News Archive

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (TSX: NEPT) (NASDAQ: NEPT), today announced it has entered into definitive agreements with certain US healthcare focused institutional investors for a private placement of 16,203,700 common shares

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020.

Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share

Arena Pharmaceuticals, Inc. announced that on October 15, 2020, the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to purchase an aggregate of 66,475 shares of its common stock and 11,760 inducement restricted stock units.

Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2020 on Monday, November 2, 2020, after market close.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets.

Grants awarded to support programs around breast cancer awareness, heart disease and population health

Eargo, Inc. announced the closing of its initial public offering of 9,029,629 shares of its common stock at a public offering price of $18.00 per share, which includes 1,177,777 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Eargo, of approximately $162.5 million.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that new data for its early detection ELSA-seq test will be presented at the upcoming European Society for Medical Oncology (ESMO) Asia Virtual Congress, on Friday, November 20.

FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of patients suffering from severe heart failure, today announced the successful completion of a 30-day preclinical study.